Shares in pharmaceutical giant Novartis (NVS) were flat in pre-market trading today despite reporting an 11% surge in Q2 sales.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The group said demand for medicines such as breast cancer drug Kisqali and cardiovascular drug Entresto had been strong. It also raised its guidance for core operating income in 2025.